Research programme: TAR DNA binding protein-43 targeting therapeutics - Mabylon/SciNeuro Pharmaceuticals
Latest Information Update: 10 Nov 2021
At a glance
- Originator Mabylon; SciNeuro Pharmaceuticals
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action TDP-43 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
- Research Alzheimer's disease
Most Recent Events
- 26 Oct 2021 Mabylon and SciNeuro Pharmaceuticals agree to co-develop TDP-43 targeted therapeutics for neurological diseases and licensed to later in Greater China for commercialization
- 26 Oct 2021 Early research in Alzheimer's disease in Switzerland (Parenteral) (Mabylon pipeline, October 2021)
- 26 Oct 2021 Preclinical trials in Amyotrophic lateral sclerosis in Switzerland (Parenteral) (Mabylon pipeline, October 2021)